On Nov. 18, 2004, the U.S. Food and Drug Administration (FDA)  announced it had approved Genentech’s drug Tarceva (erlotinib) for patients with advanced non-small cell lung cancer, the most common form of the disease, who have failed to respond to at least one prior attempt to use chemotherapy.